Series – Page 5 – media

Two Scientists Nab Another $20 Million for Their CRISPR Biotech Eligo Bioscience

Eligo Bioscience, the French microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured a $20 million Series A round of financing from Khosla Ventures and Seventure Partners, including a $2 million award from the Worldwide Innovation Challenge. This comes just months after Eligo was selected as one of the 30 Most Innovative Companies in 2017 by the World Economic Forum. This funding will enable Eligo to strengthen its biotherapeutic platform, begin clinical trials for its lead indication and extensively grow its international team of scientists, engineers, and executives.
- Source: Biospace
- 535
- September 29, 2017
Market Views microbiome Series
Pfizer launches upstart with $103M, phase 3-ready drugs

In a first for the Big Pharma and as part of a new model, Pfizer is taking drugs from its shelves and licensing them to, while investing in, its SpringWorks Therapeutics startup.
- Source: Fiercebiotech
- 581
- September 27, 2017
Clinical Trials Pfizer Series
FEops closes €6m Series B financing

FEops, a leader in personalized computer modeling for structural heart interventions, announced today that it has secured a 6 million euros investment, led by Valiance, and joined by existing investors Capricorn and PMV.
- Source: medicaldevices-business-review
- 632
- September 26, 2017
heart investment Market Views Series
LifeMine Therapeutics combines AI, drug discovery & microbes with $55m launch

Backed by the likes of Google and Merck (NYSE:MRK), Cambridge, Mass.-based LifeMine Therapeutics launched today by closing a $55 million Series A round.
- Source: Drugdeliverybusiness
- 466
- September 19, 2017
Market Views Merck Series
Cancer Startup Torque Therapeutics Nabs $21 Million and Sets Up Shop in Kendall Square

Torque Therapeutics has come out of stealth mode to launch with a $21 million Series A financing. It is looking to raise another $14 million, according to its filing with the U.S. Securities and Exchange Commission (SEC).
- Source: Biospace
- 847
- September 15, 2017
cell immune Series therapy
Bay Area’s ARMO BioSciences Banks $67 Million From Big Name Investors Like Celgene (CELG) And Google (GOOG)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the successful completion of a $67 million Series C-1 private financing. The Series C-1 proceeds will be used to initiate phase 2/3 studies with ARMO's lead immunotherapy agent AM0010 in non-small cell lung cancer(NSCLC) and renal cell cancer and to support an ongoing pivotal phase 3 clinical trial in advanced pancreatic cancer.
- Source: biospace
- 534
- September 13, 2017
immunotherapy Market Views NSCLC pancreatic renal Series
Stent Tek Closes Series A Investment Round for its ePATH AVF Device, Aiming to Improve Vascular Access for Haemodialysis

Stent Tek, a medical device company that is developing a minimally invasive catheter system for dialysis patients, announced today it has successfully closed a Series A funding round with investments from two institutional investors.
- Source: prnewswire
- 604
- September 8, 2017
catheter invasive Market Views Series
MedGenome raises $30m for biomarker discovery program

MedGenomeGenomics research and diagnostics company MedGenome said today that it closed a $30 million Series C round led by Sequoia India and Sofina. Zodius Capital, the co-founder & former CEO of Infosys, Kris Gopalakrishnan, and former Cognizant CEO Lakshmi Narayanan also participated in the round.
- Source: drugdeliverybusiness
- 622
- August 30, 2017
genetic immunotherapy Market Views Series
NeoSync secures $13m in financing with Valiance Life Science Investments and current Investors

NeoSync has announced the completion of its Series D financing round, which included investment from Valiance Life Science Investments, as well as its original investor base totaling $13m.
- Source: patientmonitoring
- 607
- August 17, 2017
Clinical Depression Market Views Series
VentureMed raises $15m in Series B

Vascular focused device developer VentureMed said today it raised $15 million in a Series B round.
- Source: massdevice
- 510
- August 16, 2017
Company Insight Market Views medical device peripheral artery Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.